Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents

Medical Engineering and Physics

Volumn 33, Issue 7, 2011, Pages 805-809

  Akerman, Simon ^a   Reyes Aldasoro, Constantino Carlos ^a   Fisher, Matthew ^a   Pettyjohn, Katie L ^a   Björndahl, Meit A ^a   Evans, Helen ^a   Tozer, Gillian M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Keyhole tracking model; Microcirculation; Red blood cell velocity; Tumour vasculature

Indexed keywords

CHRONIC TREATMENT; FUNCTIONAL RESPONSE; ISOFORMS; MICRO-FLOW; NORMALISATION; PRE-TREATMENT; RECEPTOR TYROSINE KINASE; RED BLOOD CELL; RED BLOOD CELL VELOCITY; TRACKING ALGORITHM; TRACKING MODELS; TYROSINE KINASE INHIBITOR; VASCULAR DISRUPTING AGENTS; VASCULAR ENDOTHELIAL GROWTH; VASCULAR TARGETING AGENT; VASCULARISATION; VASCULATURE; VELOCITY RESPONSE;

AMINO ACIDS; BLOOD; ENDOTHELIAL CELLS; ENZYMES; MICROCIRCULATION; VELOCITY;

TUMORS;

COMBRETASTATIN A4 PHOSPHATE; ISOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN 120; VASCULOTROPIN 188; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL REACTIVITY; CELL LABELING; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; ERYTHROCYTE; MALE; MICROCIRCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; ERYTHROCYTES; FLUORESCENT DYES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMODYNAMICS; MALE; MICE; NEOPLASMS; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79961031514     PISSN: 13504533     EISSN: 18734030     Source Type: Journal    
DOI: 10.1016/j.medengphy.2010.09.006     Document Type: Article

References (25)

1. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8(8):579-591.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82(1):4-6.
3. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266(18):11947-11954.
4. Shima D.T., Kuroki M., Deutsch U., Ng Y.S., Adamis A.P., D'Amore P.A. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 1996, 271(7):3877-3883.
5. Tozer G.M., Akerman S., Cross N., Barber P.R., Bjorndahl M., Greco O., et al. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform - producing tumors. Cancer Res 2008, 68(7):2301-2311.
6. Tozer G.M., Kanthou C., Baguley B.C. Disrupting tumour blood vessels. Nat Rev Cancer 2005, 5(6):423-435.
7. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006, 312(5777):1175-1178.
8. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411(6835):355-365.
9. Arteaga C.L. Inhibiting tyrosine kinases: successes and limitations. Cancer Biol Ther 2003, 2(4 Suppl. 1):S79-S83.
10. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6(9):734-745.
11. Drevs J., Siegert P., Medinger M., Mross K., Strecker R., Zirrgiebel U., et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25(21):3045-3054.
12. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6(6):553-563.
13. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003, 9(6):685-693.
14. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62.
15. Vieira J.M., Schwarz Q., Ruhrberg C. Selective requirements for NRP1 ligands during neurovascular patterning. Development 2007, 134(10):1833-1843.
16. Parada L.F., Land H., Weinberg R.A., Wolf D., Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984, 312(5995):649-651.
17. Greco O., Ireson C., Coralli C., Dachs G., Shima D.T., Steele A., et al. Role of VEGF and angiopoietins on tumour response to vascular disrupting agents. NCRI Cancer Conference 2005, 148.
18. Tozer G.M., Ameer-Beg S.M., Baker J., Barber P.R., Hill S.A., Hodgkiss R.J., et al. Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv Drug Deliv Rev 2005, 57(1):135-152.
19. Fong T.A.T., Shawver L.K., Sun L., Tang C., App H., Powell T.J., et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59(1):99-106.
20. Unthank J., Lash J., Nixon J., Sidner R., Bohlen H. Evaluation of carbocyanine-labeled erythrocytes for microvascular measurements. Microvasc Res 1993, 45:193-210.
21. Sandison J.C. A new method for the microscopic study of living growing tissues by the introduction of a transparent chamber in the rabbit's ear. Anat Rec 1924, 28:281-287.
22. Prazma J., Carrasco V.N., Garrett C.G., Pillsbury H.C. Measurement of cochlear blood flow: intravital fluorescence microscopy. Hear Res 1989, 42(2-3):229-236.
23. Tozer G.M., Prise V.E., Wilson J., Cemazar M., Shan S., Dewhirst M.W., et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001, 61:6413-6422.
24. Reyes-Aldasoro C.C., Akerman S., Tozer G.M. Measuring the velocity of fluorescently labelled red blood cells with a keyhole tracking algorithm. J Microsc 2008, 229(1):162-173.
25. Reyes-Aldasoro C.C. Retrospective shading correction algorithm based on signal envelope estimation. Electron Lett 2009, 45(9):454-456.